*Confident and strong management team.
*$2 B Annual U.S vaccine market.
*Especially 2018 is the year people suffer from flu . FDA may give green light to ALT for their studies . NasoVax .
*Stock is under accumulations since 6 months .
*Ceo Bill Enright has been with the company over 10yrs , its time for him to prove himself.
*Heavy insider buying activities.
"opinions are my own , trade at your own risks"